USSTOCK.TODAY
Regular Market
Log in Sign up

ImmunityBio shares fall approximately 15% despite ANKTIVA revenue growth

The Motley Fool +1 · ·by G4L

IBRX
IBRX ImmunityBio Inc
$7.11 -17.66%
View chart & analysis →
  1. 1ImmunityBio recorded a 53% year-over-year growth in quarterly product revenue.
  2. 2ImmunityBio shares fell 15% on Monday.
  3. 3ImmunityBio shares traded at approximately $7.30 late Monday afternoon.

So what's the key point?

ImmunityBio recorded a 53% year-over-year growth in quarterly product revenue.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

ImmunityBio, Inc. Reports $184.6 Million Loss in Third Quarter Associated Press · 20h agoGoldman discloses combined ~$75M stake in CAPR, SLS, and IBRX Stocktwits +1 · Aug 17UAE grants ImmunityBio's Anktiva broad approval for bladder and lung cancer Stocktwits +8 · Jul 30
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news